Consolidated operating loss narrows, while ordinary and net losses widen
First written in FY2016-Q4. 18 of 38 entries say "Worsened", first in FY2017-Q1. Latest entry: FY2026.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2016, 3 years before the typical company in this theme (2019).
The whole theme swung hardest in 2019: 4 of 9 companies on the "Worse" side.
2 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「As a result, revenue was ¥1,421.944 million, down 2.3% from the previous consolidated fiscal year, operating profit was ¥209.911 million, down 15.9%, ordinary profit was ¥206.691 million, down 14.2%, and profit attributable to owners of the parent was ¥200.358 million, down 21.9%.」
Although the company remained profitable, revenue fell 2.3%, operating profit fell 15.9%, ordinary profit fell 14.2% and net income fell 21.9%. - FY2026-H1WorsenedAnnual report
「As a result, operating profit was ¥46.843 million, down 55.2% year on year, and ordinary profit was ¥47.097 million, down 50.3%. Interim net income attributable to owners of the parent was ¥43.859 million, down 52.9%.」
Operating profit, ordinary profit and interim net income attributable to owners of the parent all remained positive, but declined substantially year on year. - FY2025-H1AdvancedAnnual report
「As a result, revenue for the six months ended 30 September 20XX was ¥684.482 million, up 8.1% year on year. In addition, gross profit increased to ¥438.539 million, up 10.8% year on year, due to higher sales of highly profitable products and services. Operating profit was ¥104.603 million, up 46.2% year on year. Ordinary profit was ¥94.721 million, up 34.1%, despite the recognition of foreign exchange losses, and interim net income attributable to owners of the parent was ¥93.218 million, up 31.2%.」
In addition to higher revenue, increased sales of highly profitable products and services led operating profit, ordinary profit and interim net income attributable to owners of the parent to exceed the year-earlier levels. - FY2024Operating and ordinary profit up, net income downAnnual report
「As a result, revenue for the fiscal year was ¥1,345.671 million, up 3.6% year on year. Despite higher costs of purchased goods associated with sales of partner services and higher depreciation expenses related to capacity expansion, operating profit was ¥220.168 million, up 4.4% year on year, and ordinary profit was ¥241.441 million, up 3.8%. Profit attributable to owners of the parent was ¥243.248 million, down 14.9% year on year.」
Although consolidated revenue, operating profit and ordinary profit increased, profit attributable to owners of the parent decreased due to changes in adjustments to corporate income taxes related to deferred tax assets in the previous fiscal year. - FY2024-Q3RestatedAnnual report
「As a result, revenue for the nine months ended 31 December 20XX was ¥1,115.556 million, up 3.7% year on year. Due mainly to higher depreciation and maintenance expenses associated with capacity expansion, as well as increased R&D expenses, operating profit was ¥251.940 million, down 4.2% year on year; ordinary profit was ¥251.908 million, down 5.2%; and profit attributable to owners of the parent was ¥228.561 million, down 0.0%.」
Although revenue increased, operating profit and ordinary profit fell below the year-earlier levels due to higher depreciation and maintenance expenses associated with capacity expansion and increased R&D expenses, while net income was roughly unchanged from the previous year. - FY2024-Q2WorsenedAnnual report
「As a result, revenue for the six months ended 30 September 20XX was ¥632.901 million, up 3.7% year on year. Due mainly to higher depreciation and maintenance expenses associated with capacity expansion, as well as increased R&D expenses, operating profit was ¥71.540 million, down 15.1% year on year; ordinary profit was ¥70.615 million, down 18.6%; and profit attributable to owners of the parent was ¥71.045 million, down 4.2%.」
Although consolidated revenue increased, operating profit, ordinary profit and profit attributable to owners of the parent all fell below the year-earlier levels due to higher depreciation and maintenance expenses associated with capacity expansion and increased R&D expenses. - FY2024-Q1WorsenedAnnual report
「As a result, revenue for the first quarter of the current fiscal year declined to ¥235.241 million, down 10.4% year on year. The operating loss was ¥30.728 million, compared with operating income of ¥1.433 million in the same period of the previous year; the ordinary loss was ¥30.626 million, compared with ordinary income of ¥6.665 million; and the quarterly net loss attributable to owners of the parent was ¥38.200 million, compared with a quarterly net loss attributable to owners of the parent of ¥17.599 million.」
Due to lower revenue, operating and ordinary income turned from profits in the same period of the previous year to losses, while the quarterly net loss attributable to owners of the parent also widened. - FY2023Operating income and net income increased, while ordinary income declinedAnnual report
「Revenue increased to ¥1,299.225 million, up 6.2% year on year. Although R&D expenses increased as the company focused on R&D for future growth, operating income also increased to ¥210.982 million, up 10.4% year on year, due to higher revenue and reductions in general and administrative expenses resulting from improved productivity. Meanwhile, ordinary income declined to ¥232.611 million, down 8.1% year on year, as non-operating income and expenses decreased by ¥40.299 million due mainly to lower foreign exchange gains recognized in the previous consolidated fiscal year.」
Consolidated revenue, operating income and net income attributable to owners of the parent increased, while ordinary income declined due mainly to lower foreign exchange gains, resulting in mixed performance across the income statement. - FY2023-Q3WorsenedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year increased to ¥1,075.281 million, up 6.4% year on year. Meanwhile, partly because R&D expenses in the Healthcare Solutions business increased, operating income was ¥262.931 million, down 2.2% year on year. In addition, ordinary income was ¥265.651 million, down 12.3%, due to factors including the fact that subsidy income recognized in the first 3 quarters of the previous fiscal year is scheduled to be recognized in the fourth quarter of the current fiscal year, as well as a decline in foreign exchange gains. Quarterly net income attributable to owners of the parent was ¥228.574 million, down 18.7% year on year.」
Consolidated revenue increased, but operating income, ordinary income and quarterly net income attributable to owners of the parent all fell below the levels in the same period of the previous year. - FY2023-Q2AdvancedAnnual report
「As a result, revenue for the first 2 quarters of the current fiscal year increased significantly to ¥610.505 million, up 14.4% year on year. Operating income was ¥84.289 million, up 9.7% year on year, and ordinary income was ¥86.710 million, up 5.6%. Quarterly net income attributable to owners of the parent was ¥74.167 million, down 9.7% year on year, due to the effect of the reversal of deferred tax assets.」
Consolidated revenue, operating income and ordinary income exceeded the levels in the same period of the previous year. Meanwhile, quarterly net income attributable to owners of the parent declined year on year due to the reversal of deferred tax assets. - FY2023-Q1AdvancedAnnual report
「As a result, revenue for the first quarter of the current fiscal year increased significantly to ¥262.484 million, up 51.3% year on year. Operating income was ¥1.433 million, compared with an operating loss of ¥44.511 million in the same period of the previous year, and ordinary income was ¥6.665 million, compared with an ordinary loss of ¥43.406 million. The quarterly net loss attributable to owners of the parent was ¥17.599 million, compared with a quarterly net loss attributable to owners of the parent of ¥48.846 million, due to the reversal of deferred tax assets.」
Consolidated revenue increased 51.3% year on year, and operating and ordinary income turned from losses in the same period of the previous year to profits. Meanwhile, the quarterly net loss attributable to owners of the parent continued due to the reversal of deferred tax assets. - FY2022AdvancedAnnual report
「As a result, revenue for the current consolidated fiscal year was ¥1,223.281 million, up 8.8% year on year. Due to efforts including reductions in general and administrative expenses, operating income was ¥191.150 million, up 385.5% year on year. In addition, partly due to the recognition of ¥46.092 million in foreign exchange gains related to loans to the U.S. subsidiary amid the sharp depreciation of the yen, ordinary income was ¥253.078 million, up 325.3%, and net income attributable to owners of the parent was ¥267.785 million, up 360.0%, resulting in significant increases in revenue and profit.」
Consolidated revenue, operating income, ordinary income and net income attributable to owners of the parent all increased. The company reported operating income of ¥191.150 million, ordinary income of ¥253.078 million and net income of ¥267.785 million. - FY2022-Q3AdvancedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year was ¥1,010.190 million, up 9.1% year on year. Due to efforts including reductions in selling, general and administrative expenses, operating income was ¥268.874 million, up 174.9% year on year; ordinary income was ¥302.765 million, up 155.2%; and quarterly net income attributable to owners of the parent was ¥281.056 million, up 200.1%, resulting in significant increases in revenue and profit.」
Consolidated revenue increased 9.1% year on year, and operating income, ordinary income and quarterly net income attributable to owners of the parent all increased significantly. - FY2022-Q2AdvancedAnnual report
「As a result of efforts to reduce selling, general and administrative expenses, operating income was ¥76.859 million, compared with operating income of ¥2.358 million in the same period of the previous year; ordinary income was ¥82.124 million, compared with an ordinary loss of ¥2.948 million; and quarterly net income attributable to owners of the parent was ¥82.149 million, compared with a quarterly net loss of ¥7.299 million. The company recorded quarterly net income attributable to owners of the parent for the first time since its listing for the first 2 quarters of a fiscal year.」
The company recorded operating income, ordinary income and quarterly net income attributable to owners of the parent, and recorded quarterly net income attributable to owners of the parent for the first time since its listing for the first 2 quarters of a fiscal year. - FY2022-Q1WorsenedAnnual report
「As a result, revenue for the first quarter of the current fiscal year was ¥173.527 million, down 29.4% year on year. As revenue declined, the operating loss was ¥44.511 million, compared with an operating loss of ¥36.104 million in the same period of the previous year; the ordinary loss was ¥43.406 million, compared with an ordinary loss of ¥38.889 million; and the quarterly net loss attributable to owners of the parent was ¥48.846 million, compared with a quarterly net loss attributable to owners of the parent of ¥36.897 million.」
Revenue declined 29.4% year on year, and the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all widened from the same period of the previous year. - FY2021AdvancedAnnual report
「As a result, revenue for the current consolidated fiscal year was ¥1,124.067 million, up 0.5% year on year. Due to efforts including reductions in general and administrative expenses, operating income was ¥39.368 million, compared with a loss of ¥17.039 million in the previous fiscal year; ordinary income was ¥59.503 million, compared with a loss of ¥16.502 million; and net income attributable to owners of the parent was ¥58.214 million, compared with a loss of ¥47.794 million. Revenue and profits increased, and the company returned to profitability for the first time since the fiscal year ended March 2014.」
Consolidated operating income, ordinary income and net income were all profitable, marking a return to profitability for the first time since the fiscal year ended March 2014. - FY2021-Q3WorsenedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year was ¥926.169 million, down 6.8% year on year. Although the company continued efforts to reduce general and administrative expenses, operating income was ¥97.805 million, down 24.0% year on year, and ordinary income was ¥118.628 million, down 10.5%. Meanwhile, quarterly net income attributable to owners of the parent was ¥93.665 million, up 6.3% year on year, because the company's corporate tax burden was reduced due mainly to the absorption-type merger with HMT Biomedical Corporation effective 1 January 2021.」
Operating and ordinary income remained profitable but declined year on year. Net income increased due to the reduced corporate tax burden associated with the absorption-type merger. - FY2021-Q2AdvancedAnnual report
「As a result, revenue for the first 2 quarters of the current fiscal year was ¥537.439 million, up 18.2% year on year, due to the expansion of the metabolomics business. In addition, owing to measures including reductions in general and administrative expenses, the company recorded operating income of ¥2.358 million for the first time in its history for the first 2 quarters of a fiscal year, compared with an operating loss of ¥123.179 million in the same period of the previous year. The ordinary loss was ¥2.948 million, compared with an ordinary loss of ¥119.055 million, and the quarterly net loss attributable to owners of the parent was ¥7.299 million, compared with a quarterly net loss attributable to owners of the parent of ¥118.617 million.」
The company recorded operating income of ¥2.358 million for the first time for the first 2 quarters of a fiscal year, while the ordinary and net losses also narrowed significantly from the same period of the previous year. - FY2021-Q1AdvancedAnnual report
「As a result, revenue for the first quarter of the current fiscal year was ¥245.718 million, up 23.9% year on year, due to the expansion of the metabolomics business. The operating loss was ¥36.104 million, compared with an operating loss of ¥89.246 million in the same period of the previous year; the ordinary loss was ¥38.889 million, compared with an ordinary loss of ¥88.172 million; and the quarterly net loss attributable to owners of the parent was ¥36.897 million, compared with a quarterly net loss attributable to owners of the parent of ¥88.629 million.」
Against a backdrop of higher revenue, the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all narrowed from the same period of the previous year. - FY2020AdvancedAnnual report
「As a result of strong sales across all sectors, particularly the chemical and food sectors, revenue for the current consolidated fiscal year was ¥1,118.495 million, the highest level since the company's founding. The operating loss was ¥17.039 million, the ordinary loss was ¥16.502 million, and the net loss attributable to owners of the parent was ¥47.794 million.」
The consolidated operating loss narrowed significantly to ¥17.039 million from ¥526.175 million in the previous fiscal year. However, the previous fiscal year covered 15 months, and the company itself stated that it had not conducted a comparative analysis. - FY2020-Q3AdvancedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year was ¥993.251 million, and operating income was ¥128.636 million, ordinary income was ¥132.517 million, and quarterly net income attributable to owners of the parent was ¥88.147 million, against a backdrop of strong sales across all sectors, particularly the chemical and food sectors.」
On a consolidated basis, the company reported operating income of ¥128.636 million, ordinary income of ¥132.517 million and net income attributable to owners of the parent of ¥88.147 million, moving from losses to profits. However, no comparison with the same quarter of the previous year was made due to a change in the fiscal year-end. - FY2020-Q2RestatedAnnual report
「As a result, revenue for the first 2 quarters of the current fiscal year was ¥454.658 million, due mainly to strong sales to the chemical and food sectors. Meanwhile, partly because the company worked on business development for its biomarker-related business and strengthened its business base for further growth in the metabolomics business, the operating loss was ¥123.179 million, the ordinary loss was ¥119.055 million, and the quarterly net loss attributable to owners of the parent was ¥118.617 million.」
Revenue was ¥454.658 million due to strong sales to the chemical and food sectors, while the company continued business development for its biomarker-related business and other initiatives, reporting an operating loss of ¥123.179 million, an ordinary loss of ¥119.055 million and a net loss of ¥118.617 million. No comparison with the same period of the previous year was made because the periods differed. - FY2020-Q1RestatedAnnual report
「As a result, revenue for the first quarter of the current fiscal year was ¥198.349 million. Meanwhile, partly because the company worked on business development for its biomarker-related business and strengthened its business base for further growth in the metabolomics business, the operating loss was ¥89.246 million, the ordinary loss was ¥88.172 million, and the quarterly net loss attributable to owners of the parent was ¥88.629 million.」
The company reported revenue of ¥198.349 million, an operating loss of ¥89.246 million, an ordinary loss of ¥88.172 million and a quarterly net loss attributable to owners of the parent of ¥88.629 million. No comparison with the previous quarter was made because the periods differed. - FY2019WorsenedAnnual report
「The operating loss was ¥526.175 million, the ordinary loss was ¥515.312 million, and the net loss attributable to owners of the parent was ¥596.026 million.」
The consolidated operating, ordinary and net losses widened significantly due to factors including a 15-month fiscal year, expanded R&D and staffing, and impairment losses. - FY2019-Q3RestatedAnnual report
「As a result, revenue for the first 4 quarters of the current fiscal year was ¥834.125 million. Although orders in the metabolomics business were recovering, this reflected factors including sluggish customer budget execution in the first half. Meanwhile, partly because the company conducted R&D toward commercializing a depression biomarker and worked to strengthen its business base for further growth in the metabolomics business, the operating loss was ¥365.268 million, the ordinary loss was ¥356.080 million, and the quarterly net loss attributable to owners of the parent was ¥359.986 million.」
While continuing R&D and efforts to strengthen the business base of the metabolomics business, the company reported an operating loss of ¥365.268 million, an ordinary loss of ¥356.080 million and a net loss of ¥359.986 million. No comparison with the same quarter of the previous year was made because the fiscal year had an irregular accounting period. - FY2019-Q2WorsenedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year was ¥438.666 million, down 15.6% year on year. Although orders in the metabolomics business were recovering, this reflected factors including sluggish customer budget execution in the first half. Meanwhile, partly because the company conducted R&D toward commercializing a depression biomarker and worked to strengthen its business base for further growth in the metabolomics business, the operating loss was ¥446.533 million, compared with an operating loss of ¥288.937 million in the same period of the previous year; the ordinary loss was ¥439.791 million, compared with an ordinary loss of ¥286.094 million; and the quarterly net loss attributable to owners of the parent was ¥442.846 million, compared with a quarterly net loss attributable to owners of the parent of ¥286.515 million.」
Revenue declined, while the operating, ordinary and net losses all widened from the same period of the previous year due to efforts including R&D and business-base strengthening. - FY2019-Q1WorsenedAnnual report
「As a result, revenue for the first 2 quarters of the current fiscal year was ¥276.434 million, down 10.1% year on year, against a backdrop of large-project orders in the metabolome analysis business being postponed to the second half of the fiscal year or later. Meanwhile, partly because the company conducted R&D toward commercializing a depression biomarker and worked to strengthen its business base for further growth in the metabolome analysis business, the operating loss was ¥293.362 million, compared with an operating loss of ¥228.648 million in the same period of the previous year; the ordinary loss was ¥287.155 million, compared with an ordinary loss of ¥227.165 million; and the quarterly net loss attributable to owners of the parent was ¥288.775 million, compared with a quarterly net loss attributable to owners of the parent of ¥227.791 million.」
Revenue declined, while the operating, ordinary and net losses all widened from the same period of the previous year due to efforts including R&D and business-base strengthening. - FY2018-Q4MitigatedAnnual report
「As a result, revenue for the first quarter of the current fiscal year was ¥150.868 million, up 28.3% year on year, against a backdrop of progress in receiving samples from projects acquired in the previous fiscal year in the metabolome analysis business. Meanwhile, partly because the company conducted R&D toward commercializing a depression biomarker and worked to strengthen its business base for further growth in the metabolome analysis business, the operating loss was ¥129.601 million, compared with an operating loss of ¥130.023 million in the same period of the previous year; the ordinary loss was ¥126.506 million, compared with an ordinary loss of ¥131.652 million; and the quarterly net loss attributable to owners of the parent was ¥127.382 million, compared with a quarterly net loss attributable to owners of the parent of ¥132.085 million.」
Revenue increased, while the operating, ordinary and net losses all narrowed from the same period of the previous year. - FY2018-Q2WorsenedAnnual report
「As a result, revenue for the first 3 quarters of the current fiscal year was ¥519.840 million, up 1.9% year on year, against a backdrop of steady orders and sales in the metabolome analysis business. Meanwhile, partly because the company accelerated investment toward the practical application and commercialization of a depression biomarker, the operating loss was ¥288.937 million, compared with an operating loss of ¥168.949 million in the same period of the previous year; the ordinary loss was ¥286.094 million, compared with an ordinary loss of ¥163.985 million; and the quarterly net loss attributable to owners of the parent was ¥286.515 million, compared with a quarterly net loss attributable to owners of the parent of ¥165.681 million.」
Revenue increased, while the operating, ordinary and net losses all widened from the same period of the previous year due mainly to accelerated investment toward the practical application and commercialization of a depression biomarker. - FY2018-Q1WorsenedAnnual report
「Meanwhile, as the company continued efforts toward commercializing a depression biomarker and promoted development of new services for metabolome analysis, the operating loss was ¥228.648 million, compared with an operating loss of ¥143.262 million in the same period of the previous year; the ordinary loss was ¥227.165 million, compared with an ordinary loss of ¥157.710 million; and the quarterly net loss attributable to owners of the parent was ¥227.791 million, compared with a quarterly net loss attributable to owners of the parent of ¥158.623 million.」
Revenue increased, while the operating, ordinary and net losses all widened from the same period of the previous year due mainly to continued efforts to commercialize a depression biomarker and develop new services. - FY2017-Q4WorsenedAnnual report
「As a result, revenue for the first quarter of the current fiscal year was ¥117.547 million, up 25.9% year on year, against a backdrop of steady orders and sales in the metabolome analysis business. Meanwhile, partly because the company actively invested in R&D toward the commercialization of a depression biomarker, the operating loss was ¥130.023 million, compared with an operating loss of ¥109.948 million in the same period of the previous year; the ordinary loss was ¥131.652 million, compared with an ordinary loss of ¥122.672 million; and the quarterly net loss attributable to owners of the parent was ¥132.085 million, compared with a quarterly net loss attributable to owners of the parent of ¥123.131 million.」
Revenue increased, while the operating, ordinary and net losses all widened from the same period of the previous year due mainly to active investment in R&D for a depression biomarker. - FY2017MitigatedAnnual report
「As the effect of higher revenue outweighed the increase in expenses, the operating loss was ¥43.332 million, compared with an operating loss of ¥70.357 million in the same period of the previous year; the ordinary loss was ¥40.410 million, compared with an ordinary loss of ¥71.007 million; and the net loss attributable to owners of the parent was ¥61.913 million, compared with a net loss attributable to owners of the parent of ¥71.469 million, resulting in narrower losses at each level.」
The increase in revenue exceeded the increase in expenses, narrowing the operating, ordinary and net losses. - FY2017-Q2WorsenedAnnual report
「Meanwhile, partly because the company accelerated investment toward the practical application and commercialization of a depression biomarker, the operating loss was ¥168.949 million, compared with an operating loss of ¥167.843 million in the same period of the previous year; the ordinary loss was ¥163.985 million, compared with an ordinary loss of ¥163.861 million; and the quarterly net loss attributable to owners of the parent was ¥165.681 million, compared with a quarterly net loss attributable to owners of the parent of ¥162.498 million.」
Revenue increased 13.2% year on year, while the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all exceeded the levels in the same period of the previous year. Accelerated investment toward the practical application and commercialization of a depression biomarker was also cited as a factor. - FY2017-Q1WorsenedAnnual report
「Revenue for the first 2 quarters of the current fiscal year was ¥273.670 million, down 8.6% year on year. The operating loss was ¥143.262 million, compared with an operating loss of ¥115.938 million in the same period of the previous year; the ordinary loss was ¥157.710 million, compared with an ordinary loss of ¥111.775 million; and the quarterly net loss attributable to owners of the parent was ¥158.623 million, compared with a quarterly net loss attributable to owners of the parent of ¥110.854 million.」
Revenue declined 8.6% year on year, and the operating loss, ordinary loss and quarterly net loss attributable to owners of the parent all widened from the same period of the previous year. - FY2016-Q4First statedAnnual report
「Revenue was ¥93.383 million, up 4.0% year on year, and the operating loss was ¥109.948 million, compared with an operating loss of ¥113.279 million in the same period of the previous year. Meanwhile, due mainly to an increase in share issuance costs related to the third-party allotment, the ordinary loss for the first quarter of the current fiscal year was ¥122.672 million, compared with an ordinary loss of ¥112.431 million in the same period of the previous year, and the quarterly net loss attributable to owners of the parent was ¥123.131 million, compared with a quarterly net loss attributable to owners of the parent of ¥112.119 million in the same period of the previous year.」
Revenue increased 4.0% year on year and the operating loss narrowed, while the ordinary loss and quarterly net loss attributable to owners of the parent widened.